DNTH: Strong clinical data and pipeline expansion position the company for major neuromuscular market growth
Claseprubart has delivered robust clinical results in MG and CIDP, prompting accelerated trial timelines and strategic trial design changes. The pipeline is expanding with DNTH212 and DNTH312, targeting broader neuromuscular and autoimmune markets, while CIDP and MMN represent significant growth op…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.